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The multidrug-resistant (MDR) Salmonella enterica se-
rotype Newport strain that produces CMY-2 β-lactamase 
(Newport MDR-AmpC) was the source of sporadic cases and 
outbreaks in humans in France during 2000–2005. Because 
this strain was not detected in food animals, it was most likely 
introduced into France through imported food products.
Third-generation cephalosporins are drugs of choice for treatment of persons with nontyphoidal Salmonella in-
fections that require chemotherapy or when fl uoroquino-
lones are contraindicated. A new public health concern is 
the emergence of third-generation cephalosporin–resistant 
Salmonella isolates (1). Multidrug-resistant (MDR) Sal-
monella enterica serotype Newport isolates that produce 
CMY-2, a β-lactamase that inactivates third-generation 
cephalosporins, were fi rst reported in the United States in 
1998 (2). These isolates, known as Newport MDR-AmpC, 
have quickly spread through the United States in cattle and 
humans (3–5). It has been hypothesized that use of ceftio-
fur, a third-generation cephalosporin licensed in the United 
States for use in cattle, could have selected for Newport 
MDR-AmpC (2–4,7). Several observations and case-con-
trol studies suggested beef and milk from dairy cattle were 
substantial sources of Newport MDR-AmpC infection in 
humans (6–8). 
These isolates seem to be extremely rare in Europe. 
Two surveys performed in England and Wales (278,308 hu-
man Salmonella isolates tested, 1992–2003) and Spain (959 
human Salmonella isolates, 1999–2000) did not detect New-
port MDR-AmpC (9,10). In St. Petersburg, Russia, only 1 
Newport MDR-AmpC isolate was reported among 1,078 
Salmonella isolates during 2002–2005 (11). In France, a 
small outbreak (14 cases) of Newport MDR-AmpC was de-
tected in 2003 and linked to consumption of imported horse 
meat (12). We undertook the present study to acquire more 
knowledge on circulation of Newport MDR-AmpC in hu-
mans, animals, and animal-derived food in France.
The Study
From 2000 through 2005, the French National Refer-
ence Centre for Salmonella at the Institut Pasteur in Paris 
reported 829 Newport isolates among 69,759 Salmonella 
clinical isolates. During this period and depending on the 
year, serotype Newport ranked between 6th and 10th in 
prevalence among human serotyped isolates. From 2000 
through 2005, the Agence Française de Sécurité Sani-
taire des Aliments reported 2,160 Newport isolates among 
101,791 Salmonella isolates collected from animals and 
food products.
Antimicrobial drug susceptibility testing was per-
formed on 585 human Newport isolates and 342 nonhu-
man Newport isolates by disk diffusion with 32 antimicro-
bial drugs (additional information available from fxweill@
pasteur.fr). Data for Newport human isolates are shown in 
the Table. Of 585 isolates tested, 46 (7.9%) were resistant 
to third-generation cepalosporins. The geographic origin 
of the isolates was mainly the Paris metropolitan area and 
northern France (online Appendix Table, available from 
www.cdc.gov/EID/content/14/6/954-appT.htm). There was 
a high prevalence of third-generation cephalosporin–resis-
tant isolates during 2000 (15%) and 2003 (17.5% caused 
by a small outbreak). No third-generation cephalosporin 
resistance was detected in any of the nonhuman Newport 
isolates tested.
Experiments were performed on the 46 third-genera-
tion cephalosporin–resistant Newport isolates (additional 
information available from fxweill@pasteur.fr). All but 1 
of the Newport isolates were resistant to cefoxitin (online 
Appendix Table). These isolates showed 4 resistance phe-
notypes; most (41, 89.1%) were resistant to streptomycin, 
sulfonamides, chloramphenicol, and tetracycline. PCR and 
sequencing showed that the 45 isolates resistant to cefoxitin 
were positive for the blaCMY-2 gene, and cefoxitin-susceptible 
isolates contained the extended-spectrum β-lactamase gene 
blaCTX-M-1. Ceftriaxone MICs of Newport MDR-AmpC iso-
lates ranged from 32 mg/L to >256 mg/L, and ceftazidime 
MICs ranged from 64 mg/L to >256 mg/L. No blaTEM genes 
were detected. Three isolates with additional resistance to 
aminoglycosides contained a class 1 integron with the 1-kb 
gene cassette aadA24 (known to encode resistance to strep-
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tomycin and spectinomycin) (11). The chloramphenicol/
fl orfenicol resistance gene fl oR was detected in all but 1 
CMY-2–producing Newport isolate.
Clonal relatedness of Newport isolates was assessed by 
multilocus sequence typing (MLST) and PulseNet standard 
method pulsed-fi eld gel electrophoresis (PFGE) (Figure 1). 
All 16 Newport MDR-AmpC isolates tested had a com-
mon sequence type (ST), ST45. XbaI-PFGE identifi ed 10 
distinct profi les (similarity 76.7%) among all 45 Newport 
MDR-AmpC isolates. Single enzyme matches were found 
for 3 of the profi les (15 isolates) in the US PulseNet national 
database (www.cdc.gov/pulsenet; online Appendix Table; 
Figure 2). Two PFGE types (New6 and New8) were di-
vided into 2–4 subtypes because of additional band(s) <100 
kb. Isolates from the 2003 outbreak showed 4 similar but 
distinct PFGE profi les that differed by 1–2 bands, migrated 
between 60 and 100 kb, and were attributed to plasmid(s) 
(additional information available from fxweill@pasteur.
fr). If only cases with indistinguishable PFGE profi les had 
been tested, potentially related cases would not have been 
linked to this outbreak. Therefore, during an outbreak in-
vestigation of Newport MDR-AmpC, analysis of plasmid 
content (either by alkaline lysis or S1 nuclease, depending 
on size of additional bands) might complete XbaI-PFGE 
profi les for isolates whose profi les differ by 1 or 2 addi-
tional bands of low molecular mass.
Alkaline lysis extraction showed that all but 1 of the 
Newport MDR-AmpC isolates harbored a plasmid >125 kb 
that hybridized with a blaCMY-2 probe; the remaining iso-
late harbored a plasmid of 100 kb (online Appendix Table). 
Analysis with S1 nuclease showed that these plasmids were 
100 kb–370 kb. Up to 3 additional plasmids (3.5 kb–100 
kb) that did not have blaCMY-2 were detected in most iso-
lates (online Appendix Table). Cephalosporin resistance 
was transferred by electroporation of plasmid DNA to 
Eschericha coli DH10B for all 38 CMY-2–positive iso-
lates tested. When present in the donor strain, resistance 
to sulfonamides, chloramphenicol, and tetracycline was 
also transferred. Restriction analysis of plasmids isolated 
from transformants showed 6 similar restriction profi les 
for Newport isolates (R1–R6) (Figure 2, online Appendix 
Table). R1 was predominant (found in 26 isolates among 
35 tested, 74.3%). Newport plasmids R1–R6 and Agona 
plasmid R8 were shown by PCR to contain variant A/C2 
replicons (13), whereas Typhimurium plasmid R7 con-
tained the I1 replicon.
PstI-digested plasmids analyzed by Southern hybrid-
ization with a blaCMY-2 probe (Figure 2) showed 4 hybrid-
ization profi les among Newport isolates. Profi le H1 cor-
responded to plasmid type C described by Carattoli et al. 
(14). Profi les H2, H3, and H4 differed from H1 by 1 ad-
ditional band (>10 kb for H2, 3.2 kb for H3, and >18 kb for 
H4), which indicated that the blaCMY-2 gene was partially or 
totally duplicated. 
Conclusions
Newport MDR-AmpC isolates have been the source 
of sporadic cases and small outbreaks in humans in France 
during 2000–2005. All isolates had the same MLST type, 
ST45, and highly similar XbaI-PFGE profi les. Their plas-
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Table. Resistance to specific antimicrobial drugs in Salmonella enterica serotype Newport from humans in France, 2000–2005* 
% Resistant isolates 
Drug
2000 (n = 100) 
(N = 109) 
2001 (n = 124) 
(N = 134) 
2002 (n = 66) 
(N = 71) 
2003 (n = 126) 
(N = 138) 
2004 (n = 91) 
(N = 94) 
2005 (n = 78) 
(N = 80) 
Amoxicillin 27 9.7 1.5 19.8 8.8 3.8
Ceftriaxone/ceftazidime 15 4 1.5 17.5 2.2 0
Gentamicin 4 1.6 0 1.6 2.2 0
Nalidixic acid 23 7.3 4.5 1.6 4.4 2.6
Ciprofloxacin 0 0 0 0 0 0
Sulfonamides 29 10.5 4.5 19.8 8.8 0
Trimethoprim 10 4 3 1.6 4.4 0
Chloramphenicol 25 9.7 1.5 15.9 8.8 0
Tetracycline 27 11.3 3 19 9.9 3.8
*n, no. of isolates studied; N, no. of isolates received at the French National Reference Centre for Salmonella (1 per patient). 
Figure 1. Representative XbaI pulsed-fi eld gel electrophoresis 
(PFGE) profi les of third-generation cephalosporin–resistant 
Salmonella Newport isolates studied. A dendrogram was generated 
with Bionumerics software (Applied Maths, Sint-Martens-Latem, 
Belgium). The PFGE profi le (and if there were indistinguishable 
isolates in the PulseNet USA database [www.cdc.gov/pulsenet], 
the corresponding Centers for Disease Control and Prevention 
PulseNet profi le), the number of isolates, and the β-lactamase 
genes are indicated.
mids carrying blaCMY-2 were homogeneous (same incompat-
ibility group A/C2, a main restriction type R1, and a main 
hybridization type H1). These results support clonal expan-
sion of 1 Newport strain (or a limited number of geneti-
cally related Newport strains) able to acquire and maintain 
a large incA/C2 MDR plasmid.
The source of the French isolates remains unknown. 
However, this strain was not found in French food animals 
or domestically produced food products (additional infor-
mation available from fxweill@pasteur.fr). One outbreak 
during the study period was linked to imported horse meat. 
Further investigation identifi ed the source as a wholesaler 
who imported meat from Belgium, the United Kingdom, 
Hungary, Canada, Brazil, Argentina, Uruguay, and Austra-
lia (12). In contrast to Europe, Newport MDR-AmpC has 
been frequently seen in the United States during the past de-
cade. Furthermore, several characteristics were shared be-
tween US and French Newport MDR-AmpC isolates: ST45 
(15), PFGE profi les New5, New6a, and New6b (displayed 
by 15 isolates among the 45 studied), and blaCMY-2 plasmid 
hybridization type H1 (14). We can reasonably hypothesize 
that during 2000–2005 some isolates likely entered France 
from North America through imported food. Alternatively, 
they could have come to France and North America from 
some other country.
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